Share

    


In This Section

Home / News & Media / Educational Resources

Educational Resources

These educational resources, tools, and materials are brought to you by our valued Corporate Members. For questions or more information, please email CorporateRelations@accc-cancer.org for assistance.

  • Does the Menin Pathway Play a Role in Your Patient’s AML?

    Posted on 2/18/2025

    Geron-200x80

     

    Visit Website



  • Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

    Published on: February 17, 2025

    Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.

    View Resource Here




  • Centers for Medicare & Medicaid Services has assigned a permanent J-code for RYTELO

    Posted on 1/16/2025

    Geron-200x80

     

    Consider updating your billing software to reflect the permanent J-code for RYTELO, J0870, and units: 1 unit per 1 mg, so J-code can be used on or after January 1, 2025.
    View Resource



  • Genentech-Pro: Product, Access, and Disease State Resources for Providers & Patients

    Posted on 12/28/2024

    Genentech-305x80

     

    View Resource



  • Patient Education on Medicare Prescription Payment Plan

    Posted on 12/02/2024

    Bayer-Global-80x80





    HCP’s: Use these handouts to help patients understand their Medicare plan:
    English Version   Spanish Version



  • Desmoid Tumor ICD-10-CM Codes Flashcard

    Posted on 11/20/2024

    SpringWorks-275x80





    FDA-Approved Therapy and ICD-10-CM Codes for Desmoid Tumors. Desmoid tumors are rare, locally aggressive soft tissue tumors that are characterized by high rates of initial misdiagnosis.
    View Resource



  • 2025 Inflation Reduction Act (IRA) FRM

    Posted on 11/13/2024

    Pfizer-200x80



    Changes to Medicare Part D in 2025 will Cap Out-Of-Pocket (OOP) Costs for Patients. Please feel free to review & share this important resource.
    View Resource



  • Johnson and Johnson 2023 U.S. Pricing Transparency Report

    Posted on 11/09/2024

    Johnson-&-Johnson-460x80



    Johnson and Johnson’s eighth U.S. Pricing Transparency Report provides key data, analysis and insights that will help advance solutions to create a more sustainable, equitable and innovative healthcare system.
    View Resource



  • Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

    Posted on 11/09/2024

    BMS-350x80


    Anemia is a hallmark of MDS, conferring heightened mortality risk and diminished quality of life. Please feel free to view & share this important resource.
    View Resource



  • Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

    Posted on 11.11.2024

    Stemline-A-Menarini-Group-Company-320x90


    Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).
    View Resource